Rifaximin

Research use only, not for human use.

Rifaximin is an oral, semi-synthetic antibiotic derived from Rifamycin SV with antibacterial activity.

Rifaximin is an oral, semi-synthetic antibiotic derived from Rifamycin SV with antibacterial activity, interferes with transcription by binding to the β-subunit of bacterial RNA polymerase; Rifaximin is widely used to treat traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy.Bacterial Infection Approved(In Vitro):Rifaximin has a good inhibitory activity against Staphylococcus, Streptococcus, Enterococcus, Escherichia coli, Shigella, Salmonella, Bacillus cereus, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus ducreyi,Bacteroides bivius-disiens, Gardnerella vaginalis, Lactobacillus spp.,Mobiluncus spp.,Neisseria gonorrhoeae, Pseudomonas and Acinetobacter . Rifaximin rarely causes side effects.Rifaximin (0.1, 1.0 and 10.0 μM) causes significant and concentration-dependent reduction of cell proliferation, cell migration and PCNA expression in the Caco-2 cells vs. untreated cells.Rifaximin (0.1-10 μM) downregulates Akt/mTOR and p38MAPK/NF-κB pathways through a PXR-dependent mechanism.(In Vivo):Rifaximin administration (30 or 50 mg/kg/day) increases survival rates of colitic mice and reduces colitis severity by improvement of wasting syndrome, histologic scores, decrease in colon IL-2, IL-12, IFN-gamma and TNF-alpha (protein and mRNA) levels, and diminishes colon myeloperoxidase (MPO) activity.

Rifaximin has a good inhibitory activity against Staphylococcus, Streptococcus, Enterococcus, Escherichia coli, Shigella, Salmonella, Bacillus cereus, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus ducreyi, Bacteroides bivius-disiens, Gardnerella vaginalis, Lactobacillus spp.,Mobiluncus spp.,Neisseria gonorrhoeae, Pseudomonas andAcinetobacter . Rifaximin rarely causes side effects.Rifaximin (0.1, 1.0 and 10.0 μM) causes significant and concentration-dependent reduction of cell proliferation, cell migration and PCNA expression in the Caco-2 cells vs. untreated cells. Rifaximin (0.1-10 μM) downregulates Akt/mTOR and p38MAPK/NF-κB pathways through a PXR-dependent mechanism. Cell Viability Assay Cell Line:Caco-2 cells Concentration:0.1, 1.0 and 10.0 μM Incubation Time:48 hours Result:Caused a significant and concentration-dependent reduction in cell proliferation. Reduced the expression of PCNA in a concentration-dependent manner.Western Blot Analysis Cell Line:Caco-2 cells Concentration:0.1, 1.0 and 10.0 μM Incubation Time:24 hours Result:Reduced Akt, mTOR, p38 MAPK and HIF-1α expression in a concentration-dependent manner.Inhibited NF-κB nuclear activation and p70S6K.

Rifaximin has a good inhibitory activity against Staphylococcus, Streptococcus, Enterococcus, Escherichia coli, Shigella, Salmonella, Bacillus cereus, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus ducreyi, Bacteroides bivius-disiens, Gardnerella vaginalis, Lactobacillus spp.,Mobiluncus spp.,Neisseria gonorrhoeae, Pseudomonas andAcinetobacter . Rifaximin rarely causes side effects.Rifaximin (0.1, 1.0 and 10.0 μM) causes significant and concentration-dependent reduction of cell proliferation, cell migration and PCNA expression in the Caco-2 cells vs. untreated cells. Rifaximin (0.1-10 μM) downregulates Akt/mTOR and p38MAPK/NF-κB pathways through a PXR-dependent mechanism. Cell Viability Assay Cell Line:Caco-2 cells Concentration:0.1, 1.0 and 10.0 μM Incubation Time:48 hours Result:Caused a significant and concentration-dependent reduction in cell proliferation. Reduced the expression of PCNA in a concentration-dependent manner.Western Blot AnalysisCell Line:Caco-2 cells Concentration:0.1, 1.0 and 10.0 μM Incubation Time:24 hours Result:Reduced Akt, mTOR, p38 MAPK and HIF-1α expression in a concentration-dependent manner.Inhibited NF-κB nuclear activation and p70S6K.

L 105SV | Rifamycin L 105

GPCR/G Protein

Antibacterial

DNA/RNASynthesis

Infection

Bacterial Infection

80621-81-4

785.8785

C43H51N3O11

>98% (HPLC)

DMSO: ≥ 26 mg/mL

OC1=C(NC(/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)/C=C/O[C@@](C2=O)(C)O3)=O)C4=C(N=C5N4C=CC(C)=C5)C6=C2C3=C(C)C(O)=C61

2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-

(-20℃)

With Ice Pack

≥ 2 years